OMICS Publishing Group- Lung Cancer in Womens
Lung Cancer in Women's is the leading cause of deaths in females. The main cause of this cases is smoking cigarette. In United States 20,000 never-smokers are clinically identified with lung cancer every year.
(prHWY.com) March 23, 2013 - Los Angeles, CA -- Lung Cancer is the out of control growth of abnormal cells that start off in one or both lungs; usually in the cells that line the air passages. The abnormal cells do not become healthy lung tissue; they divided quickly and form tumors. As tumors become larger and more numerous, they challenge the lung's capability to provide the blood stream with oxygen. Lung Cancer in Women's is the leading cause of deaths in females. The main cause of this cases is smoking cigarette. In United States 20,000 never-smokers are clinically identified with lung cancer every year. Generally a man smokes more than females, in the developed countries the number of women's who smokes have improved rapidly over the past few years. At the same time the number of cancer deaths in females increased by more than 600% between 1950 and 1997.
Risk factors for women:
Lung cancer is clinically diagnosed three times more in never-smoking females than in never-smoking men. This may be linked to exposure to with harmful toxins (substances that can cause cancer, such as secondhand smoke, radon, and asbestos), which increase the chance of lung cancer. Moreover, females may have genetic and hormone variations that effect the growth of lung cancer in never-smokers, as well as in those who smoke. These include:
* Genetics that make women more susceptible to the side effects of cigarettes smoke.
* Differences in how the chemicals in tobacco are digested by the women body.
* Higher levels of the women hormones estrogen and progesterone, which effect cancer growth.
Research have discovered that some kinds of therapy perform better for females with lung cancer than men. Moreover, females seem to advantage from like gefitinib (Iressa) and erlotinib (Tarceva) more than men. However, for most patients, gefitinib and erlotinib are suggested only as treatments when the first therapy is no more efficient.
The main aim of the OMICS Publishing Group is to share scientific knowledge by publication of research articles in international journals, organizing international conferences, in addition to publishing eBooks from academics and scientific community.
Web Site: http://omicspublishinggroup.wordpress.com/2013/03/21/lung-cancer-in-womens/
5716 Corsa Ave , Suite 110, Westlake, Los Angeles, California, USA